CHUS Fleurimont

Sherbrooke, Quebec J1H 5N4

0 studies enrolling now · 9 studies all time

What they study most

Atrial Fibrillation, Congestive Heart Failure, Gestational Hypertension, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Percutaneous Coronary Intervention, Secondary Prevention, Stroke

Studies at this site

• SyncAV Post-Market Trial — Running, not enrolling
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) — Completed
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) — Completed
• The CHIPS Trial (Control of Hypertension In Pregnancy Study) — Completed